Ibere Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $139,151,768 last year. Net change in cash is therefore $283,022.
Cash Flow
| 2021 | -868.74K | -138M | 139.15M |
|---|
IBER Cash Flow Statement (2021 – 2021)
| 2021 | |
|---|---|
Cash at beginning of period | 175.36K |
Operating activities | |
Net income | 1.56M |
| Adjustments to reconcile net income to cash generated by operating activities: | |
Depreciation and amortization | 0 |
Stock-based compensation expense | 0 |
| Deferred income tax benefit | 0 |
| Changes in operating assets and liabilities: | |
Accounts receivable, net | 0 |
Inventories | 0 |
Accounts payable | 0 |
Cash generated by operating activities | -868.74K |
Investing activities | |
Purchases Of Investments | 0 |
Investments In Property Plant And Equipment | 0 |
Acquisitions Net | 0 |
Cash generated by investing activities | -138M |
Financing activities | |
Common Stock Issued | 135.24M |
Payments for dividends | 0 |
Repurchases of common stock | 0 |
Repayments of term debt | -200.15K |
Cash used in financing activities | 139.15M |
Net Change In Cash | 283.02K |
Cash at end of period | 458.38K |
| Data source |